7th Dec 2015 09:36
LONDON (Alliance News) - ImmuPharma PLC said Monday that the first US sites are open for the recruitment of patients into its phase III clinical trial of auto immune disease treatment Lupuzor.
It expects to undertake recruitment for the study in up to 45 investigator sites, including 10 in the US and 35 in Europe, in order to recruit the required 200 patients in the trial.
The trial is due to be completed by the end of 2017.
Shares in ImmuPharma were flat at 20.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma